Anthracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitination and degradation

Oncogene

Volumn 31, Issue 1, 2012, Pages 1-12

  Zhang, B ^a   Qian, D ^a   Ma, H H ^b   Jin, R ^b   Yang, P X ^b   Cai, M Y ^a   Liu, Y H ^c   Liao, Y J ^a   Deng, H X ^a   Mai, S J ^a   Zhang, H ^b   Zeng, Y X ^a   Lin, M C ^d   Kung, H F ^a,d   Xie, D ^a   Huang, J J ^b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

anthracyclines; cancer; PinX1; telomerase; telomere dysfunction

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOXORUBICIN; EPIRUBICIN; PROTEIN; PROTEIN PINX1; SHORT HAIRPIN RNA; TELOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG TARGETING; ENZYME INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN STABILITY; TELOMERE;

ANTHRACYCLINES; CELL LINE, TUMOR; DNA DAMAGE; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; TELOMERASE; TELOMERE; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84855343604     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.214     Document Type: Article

References (35)

1. Akiyama Y, Maesawa C, Wada K, Fujisawa K, Itabashi T, Noda Y et al.(2004). Human PinX1, a potent telomerase inhibitor, is not involved in human gastrointestinal tract carcinoma. Oncol Rep 11: 871-874.
2. Autexier C, Greider CW. (1996). Telomerase and cancer: revisiting the telomere hypothesis. Trends Biochem Sci 21: 387-391. (Pubitemid 26338676)
3. Bianchi A, Shore D. (2008). How telomerase reaches its end: mechanism of telomerase regulation by the telomeric complex. Mol Cell 31: 153-165. (Pubitemid 352005819)
4. Blackburn EH. (2000). Telomere states and cell fates. Nature 408: 53-56.
5. Chang Q, Pang JC, Li J, Hu L, Kong X, Ng HK. (2004). Molecular analysis of PinX1 in medulloblastomas. Int J Cancer 109: 309-314. (Pubitemid 38240936)
6. Collins K. (2000). Mammalian telomeres and telomerase. Curr Opin Cell Biol 12: 378-383. (Pubitemid 30265070)
7. Collins K. (2006). The biogenesis and regulation of telomerase holoenzymes. Nat Rev Mol Cell Biol 7: 484-494. (Pubitemid 44036454)
8. Cong YS, Wright WE, Shay JW. (2002). Human telomerase and its regulation. Microbiol Mol Biol Rev 66: 407-425. (Pubitemid 35001137)
9. De Lange T. (1998). Telomeres and senescence: ending the debate. Science 279: 334-335. (Pubitemid 28063358)
10. de Lange T. (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19: 2100-2110. (Pubitemid 41330312)
11. Denchi EL, de Lange T. (2007). Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 448: 1068-1071. (Pubitemid 47345583)
12. Gallardo F, Olivier C, Dandjinou AT, Wellinger RJ, Chartrand P. (2008). TLC1 RNA nucleo-cytoplasmic trafficking links telomerase biogenesis to its recruitment to telomeres. EMBO J 27: 748-757. (Pubitemid 351506683)
13. Goueli BS, Janknecht R. (2004). Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 24: 25-35. (Pubitemid 38010032)
14. Harley CB. (2008). Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167-179. (Pubitemid 351305939)
15. Hawkins GA, Chang BL, Zheng SL, Isaacs SD, Wiley KE, Bleecker ER et al. (2004). Mutational analysis of PINX1 in hereditary prostate cancer. Prostate 60: 298-302. (Pubitemid 39050648)
16. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015.
17. Laurent G, Jaffrezou JP. (2001). Signaling pathways activated by daunorubicin. Blood 98: 913-924.
18. Lin SY, Elledge SJ. (2003). Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113: 881-889. (Pubitemid 36798050)
19. Liu Y, Snow BE, Hande MP, Yeung D, Erdmann NJ, Wakeham A et al. (2000). The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol 10: 1459-1462. (Pubitemid 32692877)
20. Mergny JL, Helene C. (1998). G-quadruplex DNA: a target for drug design. Nat Med 4: 1366-1367. (Pubitemid 28553455)
21. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD et al. (1997). hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795. (Pubitemid 27357969)
22. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229. (Pubitemid 38720829)
23. Nakamura M, Masutomi K, Kyo S, Hashimoto M, Maida Y, Kanaya T et al. (2005). Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 16: 859-868. (Pubitemid 40982334)
24. Nugent CI, Lundblad V. (1998). The telomerase reverse transcriptase: components and regulation. Genes Dev 12: 1073-1085. (Pubitemid 28194043)
25. Palm W, de Lange T. (2008). How shelterin protects mammalian telomeres. Annu Rev Genet 42: 301-334.
26. Shay JW, Wright WE. (2006). Telomerase therapeutics for cancer:challenges and new directions. Nat Rev Drug Discov 5: 577-584. (Pubitemid 43971192)
27. Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ. (2003). Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 307: 861-869. (Pubitemid 37494202)
28. Takai H, Smogorzewska A, de Lange T. (2003). DNA damage foci at dysfunctional telomeres. Curr Biol 13: 1549-1556. (Pubitemid 37078413)
29. Tomlinson RL, Ziegler TD, Supakorndej T, Terns RM, Terns MP. (2006). Cell cycle-regulated trafficking of human telomerase to telomeres. Mol Biol Cell 17: 955-965. (Pubitemid 43191127)
30. Uziel O, Beery E, Dronichev V, Samocha K, Gryaznov S, Weiss L et al. (2010). Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. PLoS One 5: e9132.
31. Wang C, Yu J, Yuan K, Lan J, Jin C, Huang H. (2010). Plk1-mediated mitotic phosphorylation of PinX1 regulates its stability. Eur J Cell Biol 89: 748-756.
32. Wong JMY, Kusdra L, Collins K. (2002). Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat Cell Biol 4: 731-736. (Pubitemid 34993712)
33. Xin H, Liu D, Wan M, Safari A, Kim H, Sun W et al. (2007). TPP1 is a homologue of ciliate TEBP-b and interacts with POT1 to recruit telomerase. Nature 445: 559-562. (Pubitemid 46197638)
34. Zhang B, Bai YX, Ma HH, Feng F, Jin R, Wang ZL et al. (2009). Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res 69: 75.
35. Zhou XZ, Lu KP. (2001). The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell 107: 347-359. (Pubitemid 33049978)